S21 Recent Development of "Ultra-Orphan Drug" Research for Lysosomal Storage Diseases S21-1 Development of new enzyme replacement therapy for Fabry disease utilizing molecular designing S21-2 Production of lysosomal enzymes with M6P-type glycan by engineering of yeast glycosylation system S21-3 Enzyme Replacement Therapy for Mucopolysaccharidoses S21-4 Measurement of plasma lyso-Gb3 as a new marker for Fabry disease S21-5 Intracerebroventricular replacement effects of modified recombinant human enzyme on lysosomal disease model developing neurological manifestations